Comparison between amphotericin b and posaconazole as consolidation therapy in invasive fungal sinusitis (mucormycosis)

Abstract

Aim: To analyse the effects of combination therapy with Injection liposomal Amphotericin B (LAmB) and Tablet Posaconazole in Mucormycosis. Acute invasive fungal sinusitis is an uncommon disease that often has rapid and destructive clinical progression. Priorly, a disease of the immuno-compromised, Invasive fungal sinusitis is typically associated with patients undergoing chemotherapy, stem cell transplantation as well as in patients with uncontrolled diabetes mellitus and patients using corticosteroids. Materials and methods: This retrospective observational study was carried after obtaining institutional ethical committee on a total of 40 patients with history of diabetes mellitus, covid positivity, infusion of steroid injections and immuno-compromised were admitted and treated between May 2021 to July 2021. Results: Any potential combination therapy study under consideration for testing in patients with Mucormycosis should use polyene, as backbone therapy. Injection Amphotericin B remains the only antifungal agent licensed by the US Food and Drug Administration for primary therapy of Mucormycosis. Tablet Posaconazole reported 90% minimum inhibitory concentrations with Mucorales range from 1 to >=4 microgram/ml. In febrile neutropenic patients or those with mucormycosis, Conclusion: Mucormycosis is a disease of increasing frequency. It continues to have a higher mortality rate than most other infections, frequently affects young patients.